We found 1 systematic review that addressed this question,167 but we did not use any studies in the evidence for this question because (1) they evaluated patients receiving anticoagulation therapy for mixed indications, and iso- lating the minority of patients with low to moderate risk of recurrent VTE was not possible, or (2) the studies included only patients with indications for anticoagulation therapy other than VTE. We identified 2 additional relevant studies.168,169 Mortality, recurrent VTE, and clinically relevant bleeding outcomes were derived from an observational study that included patients receiving warfarin therapy for treatment of VTE who required anticoagulation interruption for The other study was an RCT evaluating uninterrupted vs interrupted anticoagulation during pacemaker or defibrillator surgery and reported patient satisfaction (a surrogate measure of quality-of-life impairment) and delay of intervention as Although only 5% of patients in this study had VTE as the indication for anticoagulation therapy, the evidence for these outcomes was considered relevant for our population of interest. The EtD framework is shown online at https://dbep.gradepro.org/ profile/510d8142-f0d4-47f4-8998-e153cec6018f. Benefits. For benefits, see the evidence profile in the EtD framework referenced at the end of the previous section, available online. There was no effect of bridging therapy on mortality risk because no deaths occurred during the 30-day follow-up period in either group (low certainty evidence). Bridging with LMWH may reduce the risk for any recurrent VTE, but the effect, if present, is probably very small, and the relative effect CI includes both important benefit and important harm. Because very few events occur for patients at low to moderate risk for recurrent VTE, the magnitude of the absolute effect, whatever the true relative effect, will be very small, and the certainty in evidence for recurrent VTE was upgraded (RR, 0.34 [95% CI, 0.02-6.58]; ARR, 2 fewer DVTs certainty). 